American Research Corporation at the Texas Liver Institute | San Antonio, TX

Research site

(Unclaimed)

Location

607 Camden Street, San Antonio, Texas, United States of America

Site insights

Top conditions

Top treatments

BI 685509

Obeticholic Acid

Cilofexor

Elafibranor

Firsocostat

ALN-HSD

EYE103

PF-06865571

ABI-H2158

Pilocarpine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 33 total trials

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy o...

Enrolling

Diabetic Macular Edema (DME)

Neovascular Age-related Macular Degeneration (NVAMD)

Drug: EYE103

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC).Participants will also have inadequate response or intolerance t...

Enrolling

Primary Biliary Cholangitis (PBC)

Drug: Elafibranor

Other: Matched 80 mg placebo

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling

Non-alcoholic Steatohepatitis (NASH)

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Placebo

Drug: ALN-HSD

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Enrolling

Primary Sclerosing Cholangitis

Drug: Placebo Matched to Elafibranor 80 mg

Drug: Placebo Matched to Elafibranor 120 mg

A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems

This study is open to people with and without severe liver problems. People can join the study if they are 18 to 80 years of age and have a body mass...

Enrolling

Healthy

Liver Diseases

Drug: Avenciguat (BI 685509)

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of B...

Enrolling

Obesity

Non-alcoholic Fatty Liver Disease

Drug: BI 3006337

Drug: Placebo matching BI 3006337

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Prim...

Enrolling

Hepatic Impairment

Compensated Cirrhosis

Drug: Seladelpar 10 mg

Drug: Seladelpar 10 mg or less

Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

This is a Phase IIa, Randomized, Double-blind, Placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata.

Active, not recruiting

Alopecia Areata

Drug: ADX-914

Drug: Placebo

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling

Primary Biliary Cirrhosis

Drug: Seladelpar 5 mg Capsule

Drug: Seladelpar 10 mg Capsule

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (...

Active, not recruiting

Primary Biliary Cholangitis

Drug: Obeticholic Acid placebo

Drug: Obeticholic Acid 5 mg

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: PTM CILO/FIR

Drug: Cilofexor (CILO)/Firsocostat (FIR)